5 recruiting, 3 completed, 1 active not recruiting, 1 unknown. 11 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Recruiting 5, Completed 3, Active not recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 2 | Recruiting 2 |
Follow Acute Lymphoid Leukemia: new trials by email Literature Review of Acute Lymphoid Leukemia trials Research Report on Acute Lymphoid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prophylactic DLI-X for Leukemia Relapse After HCT Exercise Mobilized Prophylactic DLI, Standard Prophylactic DLI - Acute Lymphoid Leukemia, Acute Myeloid Leukemia | Phase 1 | Recruiting | University of Arizona | 180 | 2026-10-26 | 2026-10-29 |
| Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT ORCA-T - Acute Myeloid Leukemia, Acute Lymphoid Leukemia | Phase 1 | Recruiting | Stanford University | 24 | 2025-12-01 | 2026-06-23 |
| UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1 CD19 Directed CAR T Cell - Acute Lymphoid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | University of Colorado, Denver | 29 | 2024-01-24 | 2026-03-11 |
| CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies CD19/CD22-CAR-transduced T cells, cyclophosphamide, fludarabine - B-NHL, B-Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 130 | 2022-12-28 | 2026-10-26 |
| Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) Orca-Q - Acute Myeloid Leukemia, Acute Lymphoid Leukemia | Phase 1 / Phase 2 | Recruiting | University of Florida | 40 | 2022-08-16 | 2026-10-30 |
| HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation MDG1021 dose 1, MDG1021 dose 2, MDG1021 dose 3 - Acute Myeloid Leukemia, Acute Lymphoid Leukemia | Phase 1 | Withdrawn | Medigene AG | 2020-07-02 | 2021-10-08 | |
| Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies Orca-T - Acute Myeloid Leukemia, Acute Lymphoid Leukemia | Phase 1 | Active not recruiting | Orca Biosystems, Inc. | 155 | 2019-11-21 | 2026-08-14 |
| A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) Zilovertamab vedotin - Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 1 | Completed | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 91 | 2019-03-14 | 2024-01-12 |
| CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies CD19/CD22 CAR T-Cells, Fludarabine, Cyclophosphamide - Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, B Cell | Phase 1 | Completed | National Cancer Institute (NCI) | 54 | 2018-03-26 | 2025-06-04 |
| The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens Cytarabine, Deferasirox - Acute Myeloid Leukemia, Acute Lymphoid Leukemia | Phase 1 | Unknown | Isfahan University of Medical Sciences | 40 | 2016-05-01 | 2016-02-25 |
| Phase I Study of OPB-51602 in Patients With Hematologic Malignancies OPB-51602 - Multiple Myeloma, Non-Hodgkin Lymphoma | Phase 1 | Completed | Otsuka Pharmaceutical Co., Ltd. | 20 | 2011-04-01 | 2015-06-08 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (11) · Leukemia, Myeloid, Acute (8) · Lymphoma, Non-Hodgkin (5) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (4) · Lymphoma (4) · Myelodysplastic Syndromes (4) · Burkitt Lymphoma (3) · Hematologic Neoplasms (3) · Leukemia, B-Cell (3) · Leukemia, Biphenotypic, Acute (3) · Lymphoma, B-Cell (2) · Multiple Myeloma (2) · Philadelphia Chromosome (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Disease (1)
Hematologic Diseases (11) · Hemic and Lymphatic Diseases (11) · Immune System Diseases (11) · Immunoproliferative Disorders (11) · Lymphatic Diseases (11) · Lymphoproliferative Disorders (11) · Neoplasms (11) · Neoplasms by Histologic Type (11) · Leukemia (10) · Leukemia, Lymphoid (10) · Leukemia, Myeloid (8) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Bone Marrow Diseases (6) · Chronic Disease (6)
Cyclophosphamide (2) · fludarabine (2) · Acetaminophen (1) · Antiemetics (1) · Blood Component Removal (1) · Cytarabine (1) · Deferasirox (1) · Diphenhydramine (1) · Echocardiography (1) · Electrocardiography (1) · Magnetic Resonance Imaging (1) · fludarabine phosphate (1)
National Cancer Institute (NCI) (2) · Isfahan University of Medical Sciences (1) · Medigene AG (1) · Orca Biosystems, Inc. (1) · Otsuka Pharmaceutical Co., Ltd. (1) · Stanford University (1) · University of Arizona (1) · University of Colorado, Denver (1) · University of Florida (1) · VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1)
United States (8) · Japan (1) · Netherlands (1)
Alireza Eishi, Med student (1) · Emmanuel Katsanis, MD (1) · Jordan Milner, MD (1) · Lori Muffly (1) · Mahnaz Danesh, MD (1) · Mathew Angelos, MD (1) · Nirali N Shah, M.D. (1) · Peter van Balen, MD (1) · Rene Goedkoop, MD (1) · Sara K Silbert, M.D. (1) · Shaghayegh Haghjoo Javanmard, MD, PHD (1) · Valiollah Mehrzad, MD (1)
PMID 34398557, PMID 34687939, PMID 34889384, PMID 35605184, PMID 37486616, PMID 38319241, PMID 38376944, PMID 42248607